A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/re...

Descripción completa

Detalles Bibliográficos
Autores principales: Danilov, Alexey V., Spurgeon, Stephen E., Siddiqi, Tanya, Quinson, Anne-Marie, Maier, Daniela, Smith, Dionne, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279974/
https://www.ncbi.nlm.nih.gov/pubmed/33683501
http://dx.doi.org/10.1007/s10637-020-01056-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279974/
https://www.ncbi.nlm.nih.gov/pubmed/33683501
http://dx.doi.org/10.1007/s10637-020-01056-4

Ejemplares similares